A multicentre outcome research in daily clinical practice concerning the prevention of acute and delayed nausea and vomiting after chemotherapy: an outcome research

ISRCTN ISRCTN55375237
DOI https://doi.org/10.1186/ISRCTN55375237
Secondary identifying numbers P05.0473L, NL974 (NTR1001)
Submission date
16/07/2007
Registration date
16/07/2007
Last edited
27/10/2021
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr H.J. Doodeman
Scientific

Medical Centre Alkmaar
Hospital Pharmacy
P.O. Box 501
Alkmaar
1800 AM
Netherlands

Phone +31 (0)72 548 3591
Email h.j.doodeman@mca.nl

Study information

Study designMulticentre, observational, outcomes research study
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeQuality of life
Scientific titleA multicentre outcome research in daily clinical practice concerning the prevention of acute and delayed nausea and vomiting after chemotherapy: an outcome research
Study objectives1. Adherence to guidelines/protocols is unsatisfactory
2. No regimen is superior in the proportion of patients with minimal or no impact of emesis on daily living as measured using the Functional Living Index-Emesis questionnaire
Ethics approval(s)Approval received from the local medical ethics committee (Medisch Ethische Toetsingscommissie Noord-Holland [METC Noord-Holland]) on the 12th April 2005 (ref: M05-011).
Health condition(s) or problem(s) studiedQuality of life and chemotherapy induced nausea and vomiting
InterventionThis study uses self reported sides effects including nausea and vomiting by means of a patient diary which also includes a quality of life assessment.
Intervention typeOther
Primary outcome measure1. To make an inventory on the anti-emetic policy in several peripheral hospitals
2. To make an inventory on the effectiveness of these anti-emetic policies
Secondary outcome measures1. What is the difference in anti-emetic policies used in several peripheral hospitals?
2. Do these anti-emetic policies correspond with evidence based guidelines?
3. Is aprepitant used in high emetogenic chemotherapy treatment or moderate emetogenic chemotherapy treatment?
4. What is the incidence of acute and delayed nausea and vomiting in chemotherapy treatment and does this correspond with literature?
5. Can differences in effectiveness be explained by differences in patient characteristics, chemotherapy and/or anti-emetic policy?
Overall study start date15/04/2005
Completion date01/09/2007

Eligibility

Participant type(s)Patient
Age groupAdult
SexNot Specified
Target number of participants600
Key inclusion criteriaChemotherapy naive patients receiving chemotherapy.
Key exclusion criteria1. Life expectancy less than three months
2. Lack of basic proficiency in Dutch
3. Age below 18
4. Pregnancy
5. Psychological illness
Date of first enrolment15/04/2005
Date of final enrolment01/09/2007

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Medical Centre Alkmaar
Alkmaar
1800 AM
Netherlands

Sponsor information

Medical Centre Alkmaar (Medisch Centrum Alkmaar) (The Netherlands)
Hospital/treatment centre

Funders

Funder type

Hospital/treatment centre

Medical Centre Alkmaar (Medisch Centrum Alkmaar) (The Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Editorial Notes

27/10/2021: Proactive update review. No publications found. Search options exhausted.